SHIFTBIO revolutionizes treatment paradigms with its Cell-Free Nanotherapy Platform Technologies: Maxisome, InProDel, and Fusosome. We aim to offer novel therapies to patients formerly without options. Our unique approach harnesses potent regenerative immunotherapeutic nanovesicles, engineered from mesenchymal stem cells, surpassing traditional stem cell therapies. Utilizing Maxisome and InProDel technologies, we've developed SIRP-NV and HIF1α-NV respectively, redefining regenerative immune responses and normalizing acute organ failures. Fusosome technology introduces a pioneering approach to therapeutic delivery, enabling in vivo cell membrane editing and fundamentally sidestepping the endo-lysosomal pathway. This positions SHIFTBIO at the forefront of a new era in cell and gene therapy, actualizing our mission of "Giving Second Chance to Life, Cure The Incurables", and advancing treatments for rare and untreatable diseases.